Dynavax (DVAX) Q2 Revenue Jumps 29%
Dynavax Technologies (NASDAQ:DVAX), a biotechnology company focused on vaccines, released its results for the second quarter of 2025 on August 7, 2025. The company posted GAAP revenue of $95.4 million, sharply ahead of analyst expectations of $86.7 million, and GAAP diluted earnings per share (EPS) of $0.14 versus a $0.10 consensus estimate. This result marks significant year-over-year growth, with both GAAP revenue and earnings well above the same period in 2024. The quarter stood out for record sales of HEPLISAV-B, continued margin strength, and progress on multiple vaccine candidates. Overall, Dynavax delivered a strong quarter that beat internal and external forecasts, raised key product guidance, and continued to invest in its research pipeline.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Dynavax Technologies is a biopharmaceutical company specializing in the development and commercialization of vaccines for infectious diseases. Its standout product is HEPLISAV-B, a two-dose adult hepatitis B vaccine approved in the U.S. European Union, and United Kingdom. The vaccine's two-dose schedule contrasts with traditional three-dose regimens, providing faster and stronger immune protection.
Source Fool.com
Dynavax Technologies Corp Aktie
Dynavax Technologies Corp erfreut sich mäßiger Beliebtheit, mit mehr Buy- als Sell-Einschätzungen.
Die Community prognostiziert für Dynavax Technologies Corp ein Kursziel von 29 €, was den aktuellen Kurs von 13.25 € weit übertrifft.
